Potassium Chloride In Dextrose label

Potassium Chloride In Dextrose

Potassium Chloride In Dextrose Recall

Get an alert when a recall is issued.

Add Info

Side Effects & Adverse Reactions

The administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentration. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentration.

Solutions containing potassium ions should be used with great care, if at all, in patients with hyperkalemia, severe renal failure, and in conditions in which potassium retention is present.

In patients with diminished renal function, administration of solutions containing potassium ions may result in potassium retention.

Add Info

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Add Info

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

Add Info

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Add Info

Uses

These intravenous solutions are indicated for use in adults and pediatric patients as sources of electrolytes, calories, and water for hydration.

Add Info

History

There is currently no drug history available for this drug.

Add Info

Other Information

(See chart below for quantitative information.)

Potassium Chloride in 5% Dextrose Injections USP are sterile, nonpyrogenic and contain no bacteriostatic or antimicrobial agents. These products are intended for intravenous administration.

The formulas of the active ingredients are:

Ingredients Molecular Formula Molecular Weight
 Potassium Chloride USP  KCl    74.55
       
 Hydrous Dextrose USP  Chemical Structure  198.17
 Composition – Each 100 mL contains:  Concentration of Electrolytes
(mEq/liter)		 Calories per liter  Calculated Osmolarity
mOsmol/liter 		  pH
 Solution Hydrous Dextrose USP  Potassium Chloride USP
 Potassium  Chloride
 0.15% Potassium Chloride in 5% Dextrose Injection USP
(20 mEq K+/liter)		  5 g  0.15 g  20  20  170  295  4.3 (3.5–6.5)
 0.30% Potassium Chloride in 5% Dextrose Injection USP
(40 mEq K+/liter)		  5 g  0.3 g  40  40  170  330  4.3 (3.5–6.5)
 Water for Injection USP qs

The EXCEL® Container is Latex-free, PVC-free, and DEHP-free.

The plastic container is made from a multilayered film specifically developed for parenteral drugs. It contains no plasticizers and exhibits virtually no leachables. The solution contact layer is a rubberized copolymer of ethylene and propylene. The container is nontoxic and biologically inert. The container-solution unit is a closed system and is not dependent upon entry of external air during administration. The container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary.

Addition of medication should be accomplished using complete aseptic technique.

The closure system has two ports; the one for the administration set has a tamper evident plastic protector and the other is a medication addition site. Refer to the Directions for Use of the container.

Add Info
Add to My Alerts
Report Side Effect
Leave a Review
Navigate to :
Potassium Chloride In Dextrose Recall
Side Effects & Adverse Reactions
Legal Issues
FDA Safety Alerts
Manufacturer Warnings
FDA Labeling Changes
Uses
History
Other Information
Manufacturers
Trending Topics

Potassium Chloride In Dextrose Manufacturers

  • B. Braun Medical Inc.
    Potassium Chloride In Dextrose | B. Braun Medical Inc.
    No Recall

    Potassium Chloride In Dextrose | B. Braun Medical Inc.

    Potassium Chloride In Dextrose | B. Braun Medical Inc.

    These solutions are for intravenous use only.

    Dosage is to be directed by a physician and is dependent upon age, weight, clinical condition of the patient and laboratory determinations. Frequent laboratory determinations and clinical evaluation are essential to monitor changes in blood glucose and electrolyte concentrations, and fluid and electrolyte balance during prolonged parenteral therapy.

    Fluid administration should be based on calculated maintenance or replacement fluid requirements for each patient.

    If the serum potassium level is greater than 2.5 mEq/liter, potassium chloride should be given at a rate not to exceed 10 mEq/hour in a concentration less than 30 mEq/liter. The total 24-hour dose should not exceed 200 mEq.

    If urgent treatment is indicated (serum potassium level less than 2.0 mEq/liter with electrocardiographic changes or paralysis), potassium chloride may be infused at a rate of 40 mEq/hour. As much as 400 mEq may be administered in a 24-hour period while monitoring blood electrolyte concentrations carefully.

    Dextrose may be administered to normal individuals at a rate of 0.5 g/kg/hour without producing glycosuria. At the maximum infusion rate of 0.8 g/kg/hour, approximately 95% of the dextrose is retained.

    Pediatric Dosage and Administration

    There is no specific pediatric dose. The dose is dependent on weight, clinical condition and laboratory results. See WARNINGS and PRECAUTIONS.

    Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques. Mix thoroughly. Do not store.

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

  • Baxter Healthcare Corporation
    Potassium Chloride In Dextrose | Skin Alive, Ltd.
    No Recall

    Potassium Chloride In Dextrose | Skin Alive, Ltd.

    Potassium Chloride In Dextrose | Skin Alive, Ltd.

    Apply generously 15 mins before sun exposure.
    Reapply:

        * After 40 minutes of swimming  or sweating.
        * Immediately after towel drying
        * At least every 2 hours

    Sun Protections Measure. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use and sunscreen with broad spectrum SPF of 15 or higher and other sun protection measures including:

        * Limit time in the sun, especially from 10am-2pm
        * Wear long-sleeve shirts, pants, hats and sunglasses
        * Children under 6 months: Ask a Doctor



  • Hospira, Inc.
    Potassium Chloride In Dextrose | Hospira, Inc.
    No Recall

    Potassium Chloride In Dextrose | Hospira, Inc.

    Potassium Chloride In Dextrose | Hospira, Inc.

    These solutions should be administered only by intravenous infusion and as directed by the physician. The dose and rate of injection are dependent upon the age, weight and clinical condition of the patient. If the serum potassium level is greater than 2.5 mEq/liter, potassium should be given at a rate not to exceed 10 mEq/hour in a concentration less than 30 mEq/liter. Somewhat faster rates and greater concentrations (usually up to 40 mEq/liter) of potassium may be indicated in patients with more severe potassium deficiency. The total 24-hour dose should not generally exceed 200 mEq of potassium.

    As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia.

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS.

    Drug Interactions

    Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.

Login To Your Free Account